Monica Garcia-Alloza

List of Publications by Year
in descending order

69 papers	6,225 citations	109321 35 h-index	98798 67 g-index
71 all docs	71 docs citations	71 times ranked	8761 citing authors

#	Article	IF	Citations
1	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends in Endocrinology and Metabolism, 2022, 33, 50-71.	7.1	34
2	Effects of classical PKC activation on hippocampal neurogenesis and cognitive performance: mechanism of action. Neuropsychopharmacology, 2021, 46, 1207-1219.	5.4	13
3	Alzheimerâ€™s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models. Biomolecules, 2021, 11, 262.	4.0	39
4	Role of liraglutide in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2021, 13, 112.	6.2	18
5	Mitochondria-ER contacts and glucose: the powerhouse of Alzheimer's disease?. Cell Calcium, 2021, 97, 102434.	2.4	2
6	Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Frontiers in Aging Neuroscience, 2021, 13, 741923.	3.4	17
7	Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage. Frontiers in Cell and Developmental Biology, 2020, 8, 571258.	3.7	13
8	Germinal Matrix-Intraventricular Hemorrhage of the Preterm Newborn and Preclinical Models: Inflammatory Considerations. International Journal of Molecular Sciences, 2020, 21, 8343.	4.1	27
9	Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2146.	12.8	219
10	Cell proliferation and neurogenesis alterations in Alzheimerâ€™s disease and diabetes mellitus mixed murine models. Journal of Neurochemistry, 2020, 154, 673-692.	3.9	11
11	A novel PKC activating molecule promotes neuroblast differentiation and delivery of newborn neurons in brain injuries. Cell Death and Disease, 2020, 11, 262.	6.3	17
12	Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimerâ€™s disease and type 2 diabetes. Alzheimer's Research and Therapy, 2020, 12, 40.	6.2	77
13	Amyloid beta and diabetic pathology cooperatively stimulate cytokine expression in an Alzheimerâ€™s mouse model. Journal of Neuroinflammation, 2020, 17, 38.	7.2	29
14	Review of the Effect of Natural Compounds and Extracts on Neurodegeneration in Animal Models of Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 2533.	4.1	24
15	Transcriptional correlates of the pathological phenotype in a Huntingtonâ€™s disease mouse model. Scientific Reports, 2019, 9, 18696.	3.3	16
16	Altered plasma-type gelsolin and amyloid-Î² in neonates with hypoxic-ischaemic encephalopathy under therapeutic hypothermia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1349-1354.	4.3	6
17	Cognitive Impairment and Brain and Peripheral Alterations in a Murine Model of Intraventricular Hemorrhage in the Preterm Newborn. Molecular Neurobiology, 2018, 55, 4896-4910.	4.0	19
18	Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Molecular Neurobiology, 2018, 55, 6130-6144.	4.0	30

#	Article	IF	Citations
19	In Vivo Imaging of Microglia With Multiphoton Microscopy. Frontiers in Aging Neuroscience, 2018, 10, 218.	3.4	29
20	Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 3428-3438.	4.0	50
21	Mango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model. Brain Pathology, 2017, 27, 499-507.	4.1	30
22	Long-Term Mangiferin Extract Treatment Improves Central Pathology and Cognitive Deficits in APP/PS1 Mice. Molecular Neurobiology, 2017, 54, 4696-4704.	4.0	36
23	Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring. Molecular Neurodegeneration, 2017, 12, 57.	10.8	17
24	Human tau increases amyloid Î² plaque size but not amyloid Î²â€•mediated synapse loss in a novel mouse model of Alzheimer's disease. European Journal of Neuroscience, 2016, 44, 3056-3066.	2.6	81
25	Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimerâ€™s disease and type 2 diabetes. Psychoneuroendocrinology, 2016, 65, 15-25.	2.7	49
26	Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus. Molecular Neurobiology, 2016, 53, 2685-2697.	4.0	32
27	Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's disease. Psychoneuroendocrinology, 2015, 62, 69-79.	2.7	57
28	Low-voltage pattern and absence of sleep-wake cycles are associated with severe hemorrhage and death in very preterm infants. European Journal of Pediatrics, 2015, 174, 85-90.	2.7	31
29	Prediabetes and type 2 diabetes implication in central proliferation and neurogenesis. Neural Regeneration Research, 2015, 10, 28.	3.0	2
30	Central Proliferation and Neurogenesis Is Impaired in Type 2 Diabetes and Prediabetes Animal Models. PLoS ONE, 2014, 9, e89229.	2.5	85
31	Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology, 2014, 48, 123-135.	2.7	54
32	Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology, 2013, 38, 2462-2475.	2.7	118
33	Four-dimensional microglia response to anti-AÎ² treatment in APP/PS1xCX3CR1/GFP mice. Intravital, 2013, 2, e25693.	2.0	7
34	Rapid Î²-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice. Journal of Neuropathology and Experimental Neurology, 2013, 72, 272-285.	1.7	91
35	Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice. PLoS ONE, 2013, 8, e79947.	2.5	38
36	Reducing Available Soluble Î²-Amyloid Prevents Progression of Cerebral Amyloid Angiopathy in Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1009-1017.	1.7	9

#	Article	IF	Citations
37	Increased AÎ² production prompts the onset of glucose intolerance and insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1373-E1380.	3.5	81
38	Cerebrovascular lesions induce transient Â-amyloid deposition. Brain, 2011, 134, 3697-3707.	7.6	156
39	Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2010, 38, 482-491.	4.4	44
40	Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiology of Aging, 2010, 31, 2058-2068.	3.1	32
41	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	2.6	38
42	Oligomeric amyloid Î² associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4012-4017.	7.1	734
43	Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Molecular Neurodegeneration, 2009, 4, 19.	10.8	56
44	Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. Journal of Neurochemistry, 2009, 109, 1636-1647.	3.9	63
45	Detection of isolated cerebrovascular Î²â€amyloid with pittsburgh compound B. Annals of Neurology, 2008, 64, 587-591.	5.3	91
46	Rapid appearance and local toxicity of amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Nature, 2008, 451, 720-724.	27.8	916
47	Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-AÎ² Antibody Administration in PDAPP Mice. Journal of Neuroscience, 2008, 28, 14156-14164.	3.6	136
48	Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 43-50.	2.6	39
49	Antibody-Mediated Clearance of Amyloid-Â Peptide from Cerebral Amyloid Angiopathy Revealed by Quantitative In Vivo Imaging. Journal of Neuroscience, 2007, 27, 1973-1980.	3.6	55
50	Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130, 2310-2319.	7.6	164
51	Effect of passive immunotherapy on the rate of progression of cerebral amyloid angiopathy (caa) in transgenic mice. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434-435.	1.7	0
52	Curcumin labels amyloid pathology inÂvivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Journal of Neurochemistry, 2007, 102, 1095-1104.	3.9	591
53	A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiology of Disease, 2007, 28, 286-292.	4.4	40
54	EFFECT OF PASSIVE IMMUNOTHERAPY ON THE RATE OF PROGRESSION OF CEREBRAL AMYLOID ANGIOPATHY (CAA) IN TRANSGENIC MICE. FASEB Journal, 2007, 21, A73.	0.5	0

#	Article	IF	Citations
55	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1110-1117.	3.1	56
56	Plaque-Derived Oxidative Stress Mediates Distorted Neurite Trajectories in the Alzheimer Mouse Model. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1082-1089.	1.7	85
57	Effect of Selective Cholinergic Denervation on the Serotonergic System: Implications for Learning and Memory. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1074-1081.	1.7	35
58	Lack of localization of 5-HT6receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6receptor-mediated acetylcholine release. European Journal of Neuroscience, 2006, 24, 1299-1306.	2.6	110
59	Selective effects of the APOE Îµ4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiology of Disease, 2006, 22, 555-561.	4.4	26
60	Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of Disease, 2006, 24, 516-524.	4.4	633
61	Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease. Journal of Neuroscience, 2006, 26, 365-371.	3.6	69
62	Techniques for Brain Imaging In Vivo. NeuroMolecular Medicine, 2005, 6, 065-078.	3.4	28
63	Cholinergicâ€“serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimerâ€™s disease. Neuropsychologia, 2005, 43, 442-449.	1.6	193
64	Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 588-594.	1.7	54
65	Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neuroscience Letters, 2005, 375, 37-41.	2.1	64
66	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. Neuropsychopharmacology, 2004, 29, 410-416.	5.4	128
67	Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology, 2004, 47, 225-232.	4.1	17
68	Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats. Psychopharmacology, 2003, 169, 35-41.	3.1	24
69	GABAA receptor antagonists enhance cortical acetylcholine release induced by 5-HT3 receptor blockade in freely moving rats. Brain Research, 2002, 956, 81-85.	2.2	34